FDA Would Grant Pediatric Exclusivity For Negative Oncology Studies

FDA would grant pediatric exclusivity to sponsors despite negative results in either toxicity or efficacy studies, Oncology Drug Products Division Director Richard Pazdur, MD, told the Oncologic Drugs Advisory Committee March 16.